Sen. Sonny Angara on Sunday donated blood plasma for a coronavirus disease 2019 (COVID-19) patient after he recuperated from the disease last week.
Currently, COVID-19 convalescent plasma is regulated as an investigational product in the USA, and hospitals and medical facilities need to collect the plasma from an FDA-registered blood establishment.
COVID19 "convalescent plasma" will help patients develop immunity as it "transfuses" antibodies against the virus, helping the receiving individual fight infection.
The Welsh Blood Service, Welsh Government, Public Health Wales and University Hospital of Wales are now working with partners across the United Kingdom to share knowledge, procedures, best practice and learning.
As of April 12, at least 4,648 patients in the Philippines have contracted COVID-19, with 297 deaths and 197 recoveries. The expert committee which is guiding the State's containment and mitigation strategies against COVID-19 had recommended exploring the plasma therapy following the report in Journal of American Medical Association of a pilot study done by doctors in China. The initial study will investigate only the safety and feasibility of procedures for identifying donors, collecting plasma donations and administering transfusions. For these reasons, normally, plasma will be collected no sooner than 28 days after recovery and the established safe blood donor selection criteria.
The University of Chicago Medicine is launching a clinical trial to study whether blood plasma from people who have recovered from COVID-19 can be used to treat patients who are still in the hospital with severe disease symptoms.
According to a news release from IU Health, people who have recovered from the virus might have antibodies in their blood that can fight and control COVID-19. This can be transfused to patients whose immune systems are struggling to develop their own antibodies.